TORONTO, March 29, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced an update on the Type C meeting with the U.S. Food and Drug Administration (“FDA”) for advancing KETARX (ketamine) towards Phase 3 clinical development as a treatment for levodopa-induced dyskinesia in Parkinson’s…


Previous articlePT401 – The Self-Entropic Broadening Theory: Understanding The Psychedelic State and Psychosis
Next articleApex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial